Fig 1.

One-year survival of patients with hematological malignancies (A) and patients receiving high-dose steroid therapy (B), presented according to qPCR results (patients with microscopy-positive BAL samples who were therefore treated with full-dose cotrimoxazole were excluded). (A) No statistically significant difference was noted between the qPCR-positive and qPCR-negative patients (P = 0.26). (B) A statistically significant difference was observed between the qPCR-positive and qPCR-negative patients (P < 10⁻³).